XML 87 R28.htm IDEA: XBRL DOCUMENT v3.24.1
Nature of Business - Additional Information (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Cash, cash equivalents and short-term investments $ 11,200  
Net loss (34,357) $ (7,824) [1]
Accumulated deficit [2] (146,064) (111,707)
Acceleration of stock awards 10,500  
Severance and termination benefit expense 5,700  
Consideration Transferred 29,400  
Total operating expenses 38,075 $ 14,193
Private Placement    
Gross proceeds from the private placement 20,400  
Net proceeds from private placement 19,000  
Commissions and other transaction expenses $ 1,400  
CalciMedica    
Percentage of ownership of common stock 72.00%  
Graybug    
Severance and termination benefit expense $ 16,200  
Percentage of ownership of common stock 28.00%  
Convertible Debt    
Proceeds from issuance of convertible notes $ 8,600  
Preferred and Common stock    
Total net proceeds $ 112,600  
[1]

(1) Retroactively restated for the reverse recapitalization as described in Note 2.
[2]

(1) Retroactively restated for the reverse recapitalization as described in Note 2.